{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:16:31Z","timestamp":1793643391564,"version":"4.5.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771768"],"award-info":[{"award-number":["81771768"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82001741"],"award-info":[{"award-number":["82001741"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the applied basic research project of Shanxi Science and Technology Department","award":["201801D221381"],"award-info":[{"award-number":["201801D221381"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mesenchymal stem cells (MSCs) are pluripotent stem cells derived from mesoderm during early development that are characterized by high self-renewal ability and multidirectional differentiation potential. These cells are present various tissues in the human body and can be cultured in vitro. Under specific conditions, MSCs can differentiate into osteoblasts, neuron-like cells, adipocytes and muscle cells and so on, therefore, have a great application value in cell replacement therapy and tissue repair. In recent years, the application of MSCs in rheumatic diseases has received increasing attention. On the one hand, MSCs have the ability to differentiate into bone and cartilage cells; on the other hand, these stem cells are also involved in immune regulation, resulting in the alleviation of inflammation and anti-fibrotic properties and the promotion of vascular repair, thus bringing new hope for the treatment of rheumatic diseases. This article reviews the clinical progress in MSC application for the treatment of rheumatic diseases.<\/jats:p>","DOI":"10.1186\/s13287-021-02635-9","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T14:03:44Z","timestamp":1636466624000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Clinical application of mesenchymal stem cells in rheumatic diseases"],"prefix":"10.1186","volume":"12","author":[{"given":"Yajing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zewen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,9]]},"reference":[{"key":"2635_CR1","first-page":"2899","volume":"20","author":"YJ Yang","year":"2016","unstructured":"Yang YJ, Li XL, Xue Y, Zhang CX, Wang Y, Hu X, et al. Bone marrow cells differentiation into organ cells using stem cell therapy. Eur Rev Med Pharmacol Sci. 2016;20:2899\u2013907.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2635_CR2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/00007890-197404000-00001","volume":"17","author":"AJ Friedenstein","year":"1974","unstructured":"Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation. 1974;17:331\u201340.","journal-title":"Transplantation"},{"key":"2635_CR3","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1634\/stemcells.2006-0208","volume":"25","author":"PV Guillot","year":"2007","unstructured":"Guillot PV, Gotherstrom C, Chan J, Kurata H, Fisk NM. Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC. Stem Cells. 2007;25:646\u201354.","journal-title":"Stem Cells"},{"key":"2635_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nature00870","volume":"418","author":"Y Jiang","year":"2002","unstructured":"Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002;418:41\u20139.","journal-title":"Nature"},{"key":"2635_CR5","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1089\/ars.2009.2455","volume":"11","author":"D Paul","year":"2009","unstructured":"Paul D, Samuel SM, Maulik N. Mesenchymal stem cell: present challenges and prospective cellular cardiomyoplasty approaches for myocardial regeneration. Antioxid Redox Signal. 2009;11:1841\u201355.","journal-title":"Antioxid Redox Signal"},{"key":"2635_CR6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/RLI.0b013e3181ed55f4","volume":"45","author":"S Ju","year":"2010","unstructured":"Ju S, Teng GJ, Lu H, Jin J, Zhang Y, Zhang A, et al. In vivo differentiation of magnetically labeled mesenchymal stem cells into hepatocytes for cell therapy to repair damaged liver. Investig Radiol. 2010;45:625\u201333.","journal-title":"Investig Radiol"},{"key":"2635_CR7","first-page":"3499","volume":"110","author":"AJ Nauta","year":"2007","unstructured":"Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. J Am Soc Hematol. 2007;110:3499\u2013506.","journal-title":"J Am Soc Hematol"},{"key":"2635_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1634\/stemcells.2004-0359","volume":"24","author":"PA Sotiropoulou","year":"2006","unstructured":"Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells. 2006;24:74\u201385.","journal-title":"Stem Cells"},{"key":"2635_CR9","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/01.TP.0000045055.63901.A9","volume":"75","author":"T Wt","year":"2003","unstructured":"Wt T, Jd P, Wm B, Mc E, Ec G. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003;75:389\u201397.","journal-title":"Transplantation"},{"key":"2635_CR10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1159\/000365483","volume":"22","author":"O Yy","year":"2015","unstructured":"Yy O, St D, Ss T. Paracrine effects of mesenchymal stem cells-conditioned medium on microglial cytokines expression and nitric oxide production. NeuroImmunoModulation. 2015;22:233\u201342.","journal-title":"NeuroImmunoModulation"},{"key":"2635_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nri3209","volume":"12","author":"K Le Blanc","year":"2012","unstructured":"Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol. 2012;12:383\u201396.","journal-title":"Nat Rev Immunol"},{"key":"2635_CR12","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/art.22511","volume":"56","author":"A Augello","year":"2007","unstructured":"Augello A, Tasso R, Negrini SM, Cancedda R, Pennesi G. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum. 2007;56:1175\u201386.","journal-title":"Arthritis Rheum"},{"key":"2635_CR13","first-page":"335","volume":"78","author":"B Burggraaf","year":"2019","unstructured":"Burggraaf B, van Breukelen-van DSD, de Vries MA, Klop B, Liem AH, van de Geijn GM, et al. Effect of a treat-to-target intervention of cardiovascular risk factors on subclinical and clinical atherosclerosis in rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2019;78:335\u201341.","journal-title":"Ann Rheum Dis"},{"key":"2635_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10067-011-1816-0","volume":"31","author":"J Liang","year":"2012","unstructured":"Liang J, Li X, Zhang H, Wang D, Feng X, Wang H, et al. Allogeneic mesenchymal stem cells transplantation in patients with refractory RA. Clin Rheumatol. 2012;31:157\u201361.","journal-title":"Clin Rheumatol"},{"key":"2635_CR15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.5966\/sctm.2011-0018","volume":"1","author":"S Maxson","year":"2012","unstructured":"Maxson S, Lopez EA, Yoo D, Danilkovitch-Miagkova A, Leroux MA. Concise review: role of mesenchymal stem cells in wound repair. Stem Cells Transl Med. 2012;1:142\u20139.","journal-title":"Stem Cells Transl Med"},{"key":"2635_CR16","doi-asserted-by":"publisher","first-page":"10-19104","DOI":"10.19104\/jbtr.2014.107","volume":"1","author":"D Pankajakshan","year":"2014","unstructured":"Pankajakshan D, Agrawal DK. Mesenchymal stem cell paracrine factors in vascular repair and regeneration. J Biomed Technol Res. 2014;1:10\u201319104.","journal-title":"J Biomed Technol Res"},{"key":"2635_CR17","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1016\/j.biopha.2018.11.056","volume":"109","author":"M Ghoryani","year":"2019","unstructured":"Ghoryani M, Shariati-Sarabi Z, Tavakkol-Afshari J, Ghasemi A, Poursamimi J, Mohammadi M. Amelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow-derived mesenchymal stem cells: a successful clinical trial in Iran. Biomed Pharmacother. 2019;109:1834\u201340.","journal-title":"Biomed Pharmacother"},{"key":"2635_CR18","first-page":"659","volume":"26","author":"LM Wang","year":"2010","unstructured":"Wang LM, Zhou JJ, Bai W, Bai B, Li M, Wang HY, et al. Observation on the clinical efficacy of umbilical cord mesenchymal stem cells in the treatment of 17 patients with rheumatoid arthritis. Chin J Immunol. 2010;26:659\u201362 (in Chinese).","journal-title":"Chin J Immunol"},{"key":"2635_CR19","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1089\/scd.2013.0023","volume":"22","author":"L Wang","year":"2013","unstructured":"Wang L, Wang L, Cong X, Liu G, Zhou J, Bai B, et al. Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy. Stem Cells Dev. 2013;22:3192\u2013202.","journal-title":"Stem Cells Dev"},{"key":"2635_CR20","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/annrheumdis-2015-208918","volume":"76","author":"JM Alvaro-Gracia","year":"2017","unstructured":"Alvaro-Gracia JM, Jover JA, Garcia-Vicuna R, Carreno L, Alonso A, Marsal S, et al. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib\/IIa clinical trial. Ann Rheum Dis. 2017;76:196\u2013202.","journal-title":"Ann Rheum Dis"},{"key":"2635_CR21","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/sctm.18-0031","volume":"7","author":"EH Park","year":"2018","unstructured":"Park EH, Lim HS, Lee S, Roh K, Seo KW, Kang KS, et al. Intravenous infusion of umbilical cord blood-derived mesenchymal stem cells in rheumatoid arthritis: a phase IA Clinical Trial. Stem Cells Transl Med. 2018;7:636\u201342.","journal-title":"Stem Cells Transl Med"},{"key":"2635_CR22","doi-asserted-by":"publisher","first-page":"144336","DOI":"10.1016\/j.gene.2020.144336","volume":"732","author":"SA Gowhari","year":"2020","unstructured":"Gowhari SA, Shariati-Sarabi Z, Tavakkol-Afshari J, Ghasemi A, Ghoryani M, Mohammadi M. A significant decrease of BAFF, APRIL, and BAFF receptors following mesenchymal stem cell transplantation in patients with refractory rheumatoid arthritis. Gene. 2020;732:144336.","journal-title":"Gene"},{"key":"2635_CR23","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1136\/ard.2008.091793","volume":"68","author":"R Landew\u00e9","year":"2009","unstructured":"Landew\u00e9 R, Dougados M, Mielants H, van der Tempel H, van der Heijde D. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis. 2009;68:863\u20137.","journal-title":"Ann Rheum Dis"},{"key":"2635_CR24","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1007\/s00296-011-2186-2","volume":"32","author":"K Bidad","year":"2012","unstructured":"Bidad K, Fallahi S, Mahmoudi M, Jamshidi A, Farhadi E, Meysamie A, et al. Evaluation of the Iranian versions of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Bath Ankylosing Spondylitis Functional Index (BASFI) and the Patient Acceptable Symptom State (PASS) in patients with ankylosing spondylitis. Rheumatol Int. 2012;32:3613\u20138.","journal-title":"Rheumatol Int"},{"key":"2635_CR25","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.berh.2006.03.010","volume":"20","author":"M Rudwaleit","year":"2006","unstructured":"Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol. 2006;20:451\u201371.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2635_CR26","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/annrheumdis-2013-203582","volume":"74","author":"C Stolwijk","year":"2015","unstructured":"Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:65\u201373.","journal-title":"Ann Rheum Dis"},{"key":"2635_CR27","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jbspin.2015.02.006","volume":"82","author":"M Dougados","year":"2015","unstructured":"Dougados M, Etcheto A, Molt\u00f3 A, Alonso S, Bouvet S, Daur\u00e8s JP, et al. Clinical presentation of patients suffering from recent onset chronic inflammatory back pain suggestive of spondyloarthritis: the DESIR cohort. Jt Bone Spine. 2015;82:345\u201351.","journal-title":"Jt Bone Spine"},{"key":"2635_CR28","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1172\/JCI39143","volume":"119","author":"EA Miller","year":"2009","unstructured":"Miller EA, Ernst JD. Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed. J Clin Investig. 2009;119:1079\u201382.","journal-title":"J Clin Investig"},{"key":"2635_CR29","doi-asserted-by":"publisher","first-page":"R439","DOI":"10.1186\/ar1693","volume":"7","author":"X Baraliakos","year":"2005","unstructured":"Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Therapy. 2005;7:R439\u201344.","journal-title":"Arthritis Res Therapy"},{"key":"2635_CR30","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/rheumatology\/ket407","volume":"53","author":"JE Paramarta","year":"2014","unstructured":"Paramarta JE, Baeten D. Spondyloarthritis: from unifying concepts to improved treatment. Rheumatology (Oxford). 2014;53:1547\u201359.","journal-title":"Rheumatology (Oxford)"},{"key":"2635_CR31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/ar592","volume":"4","author":"J Braun","year":"2002","unstructured":"Braun J, Sieper J. Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. Arthritis Res Therapy. 2002;4:307\u201321.","journal-title":"Arthritis Res Therapy"},{"key":"2635_CR32","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.3727\/096368913X667727","volume":"23","author":"P Wang","year":"2014","unstructured":"Wang P, Li Y, Huang L, Yang J, Yang R, Deng W, et al. Effects and safety of allogenic mesenchymal stem cell intravenous infusion in active ankylosing spondylitis patients who failed NSAIDs: a 20-week clinical trial. Cell Transplant. 2014;23:1293\u2013303.","journal-title":"Cell Transplant"},{"key":"2635_CR33","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.3892\/etm.2017.4687","volume":"14","author":"A Li","year":"2017","unstructured":"Li A, Tao Y, Kong D, Zhang N, Wang Y, Wang Z, et al. Infusion of umbilical cord mesenchymal stem cells alleviates symptoms of ankylosing spondylitis. Exp Ther Med. 2017;14:1538\u201346.","journal-title":"Exp Ther Med"},{"key":"2635_CR34","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.humimm.2015.09.038","volume":"76","author":"W Rs","year":"2015","unstructured":"Rs W. Role of stem cells in spondyloarthritis: pathogenesis, treatment and complications. Hum Immunol. 2015;76:781\u20138.","journal-title":"Hum Immunol"},{"key":"2635_CR35","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/S0140-6736(14)60128-8","volume":"384","author":"L Lisnevskaia","year":"2014","unstructured":"Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet. 2014;384:1878\u201388.","journal-title":"Lancet"},{"key":"2635_CR36","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nm.2752","volume":"18","author":"Z Liu","year":"2012","unstructured":"Liu Z, Davidson A. Taming lupus\u2014a new understanding of pathogenesis is leading to clinical advances. Nat Med. 2012;18:871\u201382.","journal-title":"Nat Med"},{"key":"2635_CR37","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1177\/0961203309348983","volume":"19","author":"F Carrion","year":"2010","unstructured":"Carrion F, Nova E, Ruiz C, Diaz F, Inostroza C, Rojo D, et al. Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Lupus. 2010;19:317\u201322.","journal-title":"Lupus"},{"key":"2635_CR38","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1002\/art.27548","volume":"62","author":"L Sun","year":"2010","unstructured":"Sun L, Wang D, Liang J, Zhang H, Feng X, Wang H, et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum. 2010;62:2467\u201375.","journal-title":"Arthritis Rheum"},{"key":"2635_CR39","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.3727\/096368911X582769c","volume":"22","author":"D Wang","year":"2013","unstructured":"Wang D, Zhang H, Liang J, Li X, Feng X, Wang H, et al. Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. Cell Transplant. 2013;22:2267\u201377.","journal-title":"Cell Transplant"},{"key":"2635_CR40","doi-asserted-by":"publisher","first-page":"R79","DOI":"10.1186\/ar4520","volume":"16","author":"D Wang","year":"2014","unstructured":"Wang D, Li J, Zhang Y, Zhang M, Chen J, Li X, et al. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Res Ther. 2014;16:R79.","journal-title":"Arthritis Res Ther"},{"key":"2635_CR41","first-page":"579","volume":"36","author":"GX Yang","year":"2015","unstructured":"Yang GX, Pan LP, Chen ZQ, Zhou QY, Wang CX. The dose-effect relationship of umbilical cord mesenchymal stem cells in the treatment of systemic lupus erythematosus. Yunnan Med. 2015;36:579\u201384 (in Chinese).","journal-title":"Yunnan Med"},{"key":"2635_CR42","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10238-016-0427-0","volume":"17","author":"D Wang","year":"2017","unstructured":"Wang D, Niu L, Feng X, Yuan X, Zhao S, Zhang H, et al. Long-term safety of umbilical cord mesenchymal stem cells transplantation for systemic lupus erythematosus: a 6-year follow-up study. Clin Exp Med. 2017;17:333\u201340.","journal-title":"Clin Exp Med"},{"key":"2635_CR43","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s13287-018-1053-4","volume":"9","author":"J Liang","year":"2018","unstructured":"Liang J, Zhang H, Kong W, Deng W, Wang D, Feng X, et al. Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study. Stem Cell Res Therapy. 2018;9:312.","journal-title":"Stem Cell Res Therapy"},{"key":"2635_CR44","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1001\/archinte.160.20.3136","volume":"160","author":"W Mm","year":"2000","unstructured":"Mm W. Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982\u20131995. Arch Intern Med. 2000;160:3136\u201340.","journal-title":"Arch Intern Med"},{"key":"2635_CR45","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s10067-014-2754-4","volume":"33","author":"F Gu","year":"2014","unstructured":"Gu F, Wang D, Zhang H, Feng X, Gilkeson GS, Shi S, et al. Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy. Clin Rheumatol. 2014;33:1611\u20139.","journal-title":"Clin Rheumatol"},{"key":"2635_CR46","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.4049\/jimmunol.178.4.2579","volume":"178","author":"X Valencia","year":"2007","unstructured":"Valencia X, Yarboro C, Illei G, Lipsky PE. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol. 2007;178:2579\u201388.","journal-title":"J Immunol"},{"key":"2635_CR47","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.clim.2007.12.010","volume":"127","author":"NA Azab","year":"2008","unstructured":"Azab NA, Bassyouni IH, Emad Y, Abd EG, Hamdy G, Mashahit MA. CD4+CD25+ regulatory T cells (TREG) in systemic lupus erythematosus (SLE) patients: the possible influence of treatment with corticosteroids. Clin Immunol. 2008;127:151\u20137.","journal-title":"Clin Immunol"},{"key":"2635_CR48","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1172\/JCI25112","volume":"116","author":"R Bacchetta","year":"2006","unstructured":"Bacchetta R, Passerini L, Gambineri E, Dai M, Allan SE, Perroni L, et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Investig. 2006;116:1713\u201322.","journal-title":"J Clin Investig"},{"key":"2635_CR49","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1084\/jem.20042276","volume":"201","author":"JC Marie","year":"2005","unstructured":"Marie JC, Letterio JJ, Gavin M, Rudensky AY. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med. 2005;201:1061\u20137.","journal-title":"J Exp Med"},{"key":"2635_CR50","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1056\/NEJMcp1702514","volume":"378","author":"X Mariette","year":"2018","unstructured":"Mariette X, Criswell LA. Primary Sj\u00f6gren\u2019s syndrome. N Engl J Med. 2018;378:97.","journal-title":"N Engl J Med"},{"issue":"8","key":"2635_CR51","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1093\/rheumatology\/kez052","volume":"60","author":"G Nocturne","year":"2019","unstructured":"Nocturne G, Pontarini E, Bombardieri M, Mariette X. Lymphomas complicating primary Sjogren\u2019s syndrome: from autoimmunity to lymphoma. Rheumatology (Oxford). 2019;60(8):3513\u201321.","journal-title":"Rheumatology (Oxford)"},{"key":"2635_CR52","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1182\/blood-2011-11-391144","volume":"120","author":"J Xu","year":"2012","unstructured":"Xu J, Wang D, Liu D, Fan Z, Zhang H, Liu O, et al. Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjogren syndrome. Blood. 2012;120:3142\u201351.","journal-title":"Blood"},{"key":"2635_CR53","first-page":"435","volume":"19","author":"BD Gong","year":"2015","unstructured":"Gong BD, Lu ZH, Jing B, Huang JS, Ruan GF, Tang JP. The effect of mesenchymal stem cells on the miRNA expression profile of activated CD4~+ T cells in patients with Sjogren\u2019s syndrome. Chin J Rheumatol. 2015;19:435\u20139 (in Chinese).","journal-title":"Chin J Rheumatol"},{"key":"2635_CR54","doi-asserted-by":"publisher","first-page":"8253","DOI":"10.7150\/thno.37351","volume":"9","author":"G Yao","year":"2019","unstructured":"Yao G, Qi J, Liang J, Shi B, Chen W, Li W, et al. Mesenchymal stem cell transplantation alleviates experimental Sjogren\u2019s syndrome through IFN-beta\/IL-27 signaling axis. Theranostics. 2019;9:8253\u201365.","journal-title":"Theranostics"},{"key":"2635_CR55","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/mus.24566","volume":"51","author":"AR Findlay","year":"2015","unstructured":"Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve. 2015;51:638\u201356.","journal-title":"Muscle Nerve"},{"key":"2635_CR56","first-page":"2186","volume":"19","author":"Q Lai","year":"2015","unstructured":"Lai Q, Yu L, Qiu YR, Chen LT, Huang JQ, Li YM, et al. Umbilical cord blood mesenchymal stem cell transplantation for the treatment of polymyositis\/dermatomyositis: changes in Th cytokines. J Clin Rehabil Tis Eng Res. 2015;19:2186\u201391 (in Chinese).","journal-title":"J Clin Rehabil Tis Eng Res"},{"key":"2635_CR57","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1136\/ard.2010.141804","volume":"70","author":"D Wang","year":"2011","unstructured":"Wang D, Zhang H, Cao M, Tang Y, Liang J, Feng X, et al. Efficacy of allogeneic mesenchymal stem cell transplantation in patients with drug-resistant polymyositis and dermatomyositis. Ann Rheum Dis. 2011;70:1285\u20138.","journal-title":"Ann Rheum Dis"},{"key":"2635_CR58","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65:2737\u201347.","journal-title":"Arthritis Rheum"},{"key":"2635_CR59","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/art.23018","volume":"57","author":"SR Johnson","year":"2007","unstructured":"Johnson SR, Goek ON, Singh-Grewal D, Vlad SC, Feldman BM, Felson DT, et al. Classification criteria in rheumatic diseases: a review of methodologic properties. Arthritis Rheum. 2007;57:1119\u201333.","journal-title":"Arthritis Rheum"},{"key":"2635_CR60","doi-asserted-by":"publisher","first-page":"e001890","DOI":"10.1136\/bmjopen-2012-001890","volume":"3","author":"V Vanneaux","year":"2013","unstructured":"Vanneaux V, Farge-Bancel D, Lecourt S, Baraut J, Cras A, Jean-Louis F, et al. Expression of transforming growth factor \u03b2 receptor II in mesenchymal stem cells from systemic sclerosis patients. BMJ Open. 2013;3:e001890.","journal-title":"BMJ Open"},{"key":"2635_CR61","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1136\/ard.2011.150607","volume":"70","author":"S Guiducci","year":"2011","unstructured":"Guiducci S, Manetti M, Romano E, Mazzanti B, Ceccarelli C, Dal Pozzo S, et al. Bone marrow-derived mesenchymal stem cells from early diffuse systemic sclerosis exhibit a paracrine machinery and stimulate angiogenesis in vitro. Ann Rheum Dis. 2011;70:2011\u201321.","journal-title":"Ann Rheum Dis"},{"key":"2635_CR62","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1002\/art.30431","volume":"63","author":"G Keyszer","year":"2011","unstructured":"Keyszer G, Christopeit M, Fick S, Schendel M, Taute BM, Behre G, et al. Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: report of five cases. Arthritis Rheum. 2011;63:2540\u20132.","journal-title":"Arthritis Rheum"},{"key":"2635_CR63","doi-asserted-by":"publisher","first-page":"48","DOI":"10.21037\/sci.2016.09.03","volume":"3","author":"T Wehbe","year":"2016","unstructured":"Wehbe T, Abi SM, Abi CN, Margossian T. Mesenchymal stem cell therapy for refractory scleroderma: a report of 2 cases. Stem Cell Investig. 2016;3:48.","journal-title":"Stem Cell Investig"},{"key":"2635_CR64","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13075-017-1373-2","volume":"19","author":"H Zhang","year":"2017","unstructured":"Zhang H, Liang J, Tang X, Wang D, Feng X, Wang F, et al. Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis. Arthritis Res Ther. 2017;19:165.","journal-title":"Arthritis Res Ther"},{"key":"2635_CR65","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13020-020-00389-9","volume":"15","author":"YX Li","year":"2020","unstructured":"Li YX, Xie L, Lyu WW, Wu ZH, Qian BY. Grasp the quality elements of stem cell non-registered clinical research under COVID-19 epidemic. Chin Med Biotechnol. 2020;15:109\u201312 (in Chinese).","journal-title":"Chin Med Biotechnol"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-021-02635-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-021-02635-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-021-02635-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T11:04:00Z","timestamp":1666782240000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-021-02635-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,9]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["2635"],"URL":"https:\/\/doi.org\/10.1186\/s13287-021-02635-9","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,9]]},"assertion":[{"value":"14 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"567"}}